Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04987931 · ClinicalTrials.gov registry record
Real-World Outcomes of US Talazoparib-Treated Patients With Locally Advanced or Metastatic Breast Cancer
A clinical trial, sponsored by Pfizer.
- Completed
- Registry status
- 84
- Enrollment target
NCT04987931 is a clinical trial that has completed, run by Pfizer. The registered enrollment target is 84 participants.
The verdict
NCT04987931 has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- 84 participants
- Enrollment target
Study Summary
This study is a retrospective, multi-site, patient-level medical chart review of US adult patients with locally advanced or metastatic breast cancer (ABC) who initiated talazoparib on or after October 16, 2018 and were managed by participating providers from Cardinal Health's Oncology Provider Extended Network (OPEN). This study will describe patient characteristics, treatment patterns, and clinical outcomes of talazoparib-treated patients in real-world practice setting in US. The primary population for this study includes: -HER2-negative ABC patients with germline BRCA1/2 (gBRCA1/2) mutations treated with talazoparib monotherapy initiated on or after October 16, 2018 and ≥18 years of age at initiation of talazoparib.
Interventions
- DRUG Talazoparib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 84 participants |
| Start Date | 2021-08-20 |
| Est. Completion | 2021-10-11 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04987931
The ClinicalTrials.gov registry entry for NCT04987931 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 84 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Talazoparib is the first listed.
NCT04987931 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04987931 about?
NCT04987931 is a clinical study titled "Real-World Outcomes of US Talazoparib-Treated Patients With Locally Advanced or Metastatic Breast Cancer". This study is a retrospective, multi-site, patient-level medical chart review of US adult patients with locally advanced or metastatic breast cancer (ABC) who initiated talazoparib on or after October 16, 2018 and were managed by participating providers from Cardinal Health's Oncology Provider Exten...
What is the current status of trial NCT04987931?
This trial is currently completed. The enrollment target is 84 participants. The study started on 2021-08-20. Estimated completion is 2021-10-11.
What interventions are being tested in trial NCT04987931?
The interventions under investigation include: Talazoparib (DRUG).
Who is sponsoring clinical trial NCT04987931?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.